Background Real-world data on the impact of advances in risk-adjusted management on the
outcome of patients with pulmonary embolism (PE) are limited. Methods To investigate …

Objectives: We sought to assess the efficacy and safety of thrombolytic therapy in patients
with an acute pulmonary embolism (PE). Background: Thrombolytic therapy is approved for …

Pulmonary embolism (PE) is a major cause of morbidity and mortality world-wide, and the
use of thrombolytic therapy has been associated with favourable clinical outcomes in certain …

Opinion statement Treatment of pulmonary embolism (PE) is variable amongst different and
even the same institutions. With the introduction of different forms of thrombolysis, catheter …

Venous thromboembolism (VTE) is the third leading cause of cardiovascular death
worldwide (behind acute coronary syndrome and ischemic stroke), 1 and acute pulmonary …

Acute pulmonary embolism (PE) contributes significantly to the global burden of
cardiovascular disease. The severity of the acute PE event determines the expected …

Introduction High-risk pulmonary embolism (PE) is associated with a significant early
mortality, approaching 25%, and is defined by the presence of cardiogenic shock. State of …

Treatment guidelines recommend strong consideration of thrombolysis in patients with acute
symptomatic pulmonary embolism (PE) that present with arterial hypotension or shock …

Abstract Background Randomized controlled trials (RCTs) comparing systemic thrombolysis
to anticoagulation in intermediate risk pulmonary embolism (PE) have yielded mixed results …

Risk stratification is one of the cornerstones of the management of acute pulmonary
embolism (PE) and determines the choice of both diagnostic and therapeutic strategies. The …